N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6
Microbiology and Immunology · 2024
DOI: 10.1111/1348-0421.13121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2024. Verfasst von Tuhin Das und 17 weiteren Autor:innen. Beteiligte Einrichtung: RayBiotech Life Inc., Peachtree Corners, Georgia, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Angiotensin-Converting Enzyme 2, SARS-CoV-2, Interleukin-6. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health (NIH).
Abstract (Originalsprache)
The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS‐CoV‐2 spike protein is extensively decorated with up to 66 N‐linked glycans. Glycosylation of viral proteins is known to function in immune evasion strategies but may also function in the molecular events of viral entry into host cells. Here, we show that N‐glycosylation at Asn331 and Asn343 of SARS‐CoV‐2 spike protein is required for it to bind to ACE2 and for the entry of pseudovirus harboring the SARS‐CoV‐2 spike protein into cells. Interestingly, high‐content glycan binding screening data have shown that N‐glycosylation of Asn331 and Asn343 of the RBD is important for binding to the specific glycan molecule G4GN (Galβ−1,4 GlcNAc), which is critical for spike‐RBD‐ACE2 binding. Furthermore, IL‐6 was identified through antibody array analysis of conditioned media of the corresponding pseudovirus assay. Mutation of N‐glycosylation of Asn331 and Asn343 sites of the spike receptor‐binding domain (RBD) significantly reduced the transcriptional upregulation of pro‐inflammatory signaling molecule IL‐6. In addition, IL‐6 levels correlated with spike protein levels in COVID‐19 patients' serum. These findings establish the importance of RBD glycosylation in SARS‐CoV‐2 pathogenesis, which can be exploited for the development of novel therapeutics for COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RayBiotech Life Inc., Peachtree Corners, Georgia, USA.
- RayBiotech Guangzhou Co. Ltd. Guangzhou, Guangzhou, China.
- Department of Pathology, Center for Vascular Biology, Weill Cornell Medicine, New York, New York, USA.
- Vaccine Research Center, Gaithersburg, Maryland, USA.
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.
- South China Biochip Research Center, Guangzhou, China.
Förderung
- NIGMS NIH HHS
- National Institutes of Health (NIH)
Zitieren
APA
Das, T., Luo, S., Tang, H., Fang, J., Mao, Y., Yen, H. H., Dash, S., Shajahan, A., Pepi, L., Huang, S., Jones, V. S., Xie, S., Huang, G. F., Lu, J., Anderson, B., Zhang, B., Azadi, P., & Huang, R. P. (2024). N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.13121
Vancouver
Das T, Luo S, Tang H, Fang J, Mao Y, Yen HH, et al. N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6. Microbiology and Immunology. 2024. doi:10.1111/1348-0421.13121
BibTeX
@article{Das2024,
author = {Das, Tuhin and Luo, Shuhong and Tang, Hao and Fang, Jianmin and Mao, Yinging and Yen, Haw-Han and Dash, Sabyasachi and Shajahan, Asif and Pepi, Lauren and Huang, Steven and Jones, Valerie S and Xie, Shehuo and Huang, Gordon F and Lu, Jinqiao and Anderson, Blake and Zhang, Benyue and Azadi, Parastoo and Huang, Ruo-Pan},
title = {N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6},
journal = {Microbiology and Immunology},
year = {2024},
doi = {10.1111/1348-0421.13121}
}
EUVIMED